Ayble Health has been nominated for the 2026 Prix Galien USA Best Digital Health Solution — an award widely regarded as the Nobel Prize of biotechnology, judged strictly on science and patient impact.

From the beginning, Ayble has had an uncompromising commitment to clinical innovation and scientific evidence. In a digital health landscape often noisy with surface-level metrics, Ayble stood out by prioritizing methodological rigor, publishing 16 peer-reviewed studies, and proving real clinical efficacy across complex GI populations before commercializing. Their growth is a reflection of that patient-first mindset.

Huge congratulations to Sam Jactel and the whole Ayble team on this nomination.

More at the link .